WO2016144139A3 - Composition pour prévenir ou traiter des maladies inflammatoires, comprenant des vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs - Google Patents

Composition pour prévenir ou traiter des maladies inflammatoires, comprenant des vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs Download PDF

Info

Publication number
WO2016144139A3
WO2016144139A3 PCT/KR2016/002473 KR2016002473W WO2016144139A3 WO 2016144139 A3 WO2016144139 A3 WO 2016144139A3 KR 2016002473 W KR2016002473 W KR 2016002473W WO 2016144139 A3 WO2016144139 A3 WO 2016144139A3
Authority
WO
WIPO (PCT)
Prior art keywords
lactic acid
acid bacteria
extracellular vesicles
derived extracellular
composition
Prior art date
Application number
PCT/KR2016/002473
Other languages
English (en)
Korean (ko)
Other versions
WO2016144139A2 (fr
Inventor
김윤근
편복양
김민혜
최준표
Original Assignee
주식회사 엠디헬스케어
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160029069A external-priority patent/KR20160110232A/ko
Application filed by 주식회사 엠디헬스케어 filed Critical 주식회사 엠디헬스케어
Priority to EP16762026.9A priority Critical patent/EP3269378B1/fr
Priority to US15/556,953 priority patent/US10406184B2/en
Priority to CN201680014982.7A priority patent/CN107750161B/zh
Priority to JP2017547484A priority patent/JP6700297B2/ja
Publication of WO2016144139A2 publication Critical patent/WO2016144139A2/fr
Publication of WO2016144139A3 publication Critical patent/WO2016144139A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne : une composition pour prévenir, améliorer ou traiter des maladies inflammatoires, la composition comprenant, comme principes actifs, des vésicules extracellulaires dérivées de bactéries d'acide lactique isolées de fluide de culture de bactéries d'acide lactique; et un procédé pour diagnostiquer une dermatite atopique. Il a été confirmé, par l'intermédiaire d'expériences in vitro et in vivo, que les vésicules extracellulaires dérivées de bactéries d'acide lactique de la présente invention sont considérablement davantage réparties dans l'urine et le sang d'un patient atteint de maladies inflammatoires qu'une personne normale, et une réponse inflammatoire dans des cellules épithéliales et des cellules inflammatoires causée par une exposition à des vésicules extracellulaires dérivées de Staphylococcus ou Pseudomonas est inhibée efficacement par les vésicules extracellulaires dérivées de bactéries d'acide lactique. Ainsi, la composition comprenant les vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs est supposée être utilisée de façon utile dans le développement de médicaments, de produits cosmétiques ou d'aliment fonctionnel de santé pour prévenir, améliorer ou traiter des maladies inflammatoires, telles que la dermatite atopique, la rhinite chronique, la sinusite chronique, l'asthme, une bronchopneumopathie chronique obstructive, la sepsie, etc. La composition sera utilisée de façon utile pour le diagnostic de dermatite atopique par mesure de la distribution de vésicules extracellulaires dérivées de bactéries d'acide lactique dans un échantillon d'urine ou de sang.
PCT/KR2016/002473 2015-03-11 2016-03-11 Composition pour prévenir ou traiter des maladies inflammatoires, comprenant des vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs WO2016144139A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP16762026.9A EP3269378B1 (fr) 2015-03-11 2016-03-11 Composition pour prévenir ou traiter des maladies inflammatoires, comprenant des vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs
US15/556,953 US10406184B2 (en) 2015-03-11 2016-03-11 Method of treating an inflammatory disease using lactic acid bacteria-derived extracellular vesicles
CN201680014982.7A CN107750161B (zh) 2015-03-11 2016-03-11 含作为活性成分的来源于乳酸菌的细胞外囊泡的预防或治疗炎性疾病的组合物
JP2017547484A JP6700297B2 (ja) 2015-03-11 2016-03-11 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の予防または治療用の組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150033698 2015-03-11
KR10-2015-0033698 2015-03-11
KR10-2016-0029069 2016-03-10
KR1020160029069A KR20160110232A (ko) 2015-03-11 2016-03-10 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2016144139A2 WO2016144139A2 (fr) 2016-09-15
WO2016144139A3 true WO2016144139A3 (fr) 2016-11-10

Family

ID=56880351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/002473 WO2016144139A2 (fr) 2015-03-11 2016-03-11 Composition pour prévenir ou traiter des maladies inflammatoires, comprenant des vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs

Country Status (1)

Country Link
WO (1) WO2016144139A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101944664B1 (ko) * 2017-02-24 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 파킨슨병 진단방법
KR101944665B1 (ko) * 2017-02-24 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 만성폐쇄성기도질환 진단 방법
KR102348048B1 (ko) * 2017-06-29 2022-01-10 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 항노화용 조성물
KR102335710B1 (ko) * 2017-10-31 2021-12-07 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
AU2018367596A1 (en) * 2017-11-15 2020-05-21 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using immune modulating
KR102032546B1 (ko) * 2017-11-16 2019-10-15 씨제이제일제당 주식회사 락토바실러스 플란타룸 배양물을 포함하는 항균용 화장료 조성물
KR102282490B1 (ko) * 2018-01-12 2021-07-28 주식회사 엠디헬스케어 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도
KR102194286B1 (ko) * 2018-02-08 2020-12-22 주식회사 엠디헬스케어 락토코커스 속 세균 유래 나노소포 및 이의 용도
KR102118197B1 (ko) 2018-02-28 2020-06-02 주식회사 엠디헬스케어 마이크로코커스 속 세균 유래 나노소포 및 이의 용도
KR102101692B1 (ko) * 2018-03-05 2020-04-20 주식회사 엠디헬스케어 락토바실러스 속 세균 유래 나노소포 및 이의 용도
WO2019245223A1 (fr) * 2018-06-19 2019-12-26 (주)코엔바이오 Composition comprenant une souche de leuconostoc sp. permettant d'améliorer la fonction hépatique
EP3837993A4 (fr) * 2018-06-19 2022-04-20 Coenbio Co., Ltd. Composition permettant d'améliorer la fonction intestinale comprenant une souche leuconostoc sp
KR102242196B1 (ko) * 2018-12-10 2021-04-20 주식회사 엠디헬스케어 스핀고모나스 속 세균 유래 나노소포 및 이의 용도
KR102356626B1 (ko) * 2018-12-10 2022-01-28 주식회사 엠디헬스케어 웨이셀라 속 세균 유래 나노소포 및 이의 용도
CN115305211A (zh) * 2021-05-07 2022-11-08 葡萄王生技股份有限公司 益生菌胞外泌体及其用途
CN115161254A (zh) * 2022-03-11 2022-10-11 中国农业大学 一种提高乳酸菌胞外囊泡产量的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050109928A (ko) * 2003-01-30 2005-11-22 바이오가이아 에이비 유산균으로부터 유래된 소염 활성
JP2010047504A (ja) * 2008-08-20 2010-03-04 Nippon Meat Packers Inc アトピー性皮膚炎緩和剤
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
KR20130034764A (ko) * 2011-09-29 2013-04-08 정용현 신규한 균주로 항알러지, 아토피성 피부염 개선 및 면역력증진 기능을 갖는 Lactobacillus plantarum K-1과 이를 함유하는 미생물제제

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050109928A (ko) * 2003-01-30 2005-11-22 바이오가이아 에이비 유산균으로부터 유래된 소염 활성
JP2010047504A (ja) * 2008-08-20 2010-03-04 Nippon Meat Packers Inc アトピー性皮膚炎緩和剤
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
KR20130034764A (ko) * 2011-09-29 2013-04-08 정용현 신규한 균주로 항알러지, 아토피성 피부염 개선 및 면역력증진 기능을 갖는 Lactobacillus plantarum K-1과 이를 함유하는 미생물제제

Also Published As

Publication number Publication date
WO2016144139A2 (fr) 2016-09-15

Similar Documents

Publication Publication Date Title
WO2016144139A3 (fr) Composition pour prévenir ou traiter des maladies inflammatoires, comprenant des vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs
Pothmann et al. The microbiome and atopic dermatitis: A review
WO2016070151A8 (fr) Procédés et compositions se rapportant à un traitement microbien et au diagnostic de troubles
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
EP2068929A4 (fr) Methode de detection et de traitement de troubles cutanes
EA201490795A1 (ru) 3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции
Ley et al. Mortality is reduced for heart rate 80 to 89 after traumatic brain injury
Aggarwal Cultural formulations in child and adolescent psychiatry.
WO2013106766A3 (fr) Indications thérapeutiques du miarn-1291
Guha et al. Effects of two potential probiotic Lactobacillus bacteria on adipogenesis in vitro
WO2015157345A3 (fr) Profilage bioénergétique de cellules de sang circulant et systèmes, dispositifs et procédés afférents
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
Martinez-Anton et al. Role Of Spleen Tyrosine Kinase (syk) In The Airway Epithelium In Asthma
Murphy Pre-Activation Of Mesenchymal Stromal Cells To Enhance Bacterial Clearance In Septic Lung Injury
Zhang et al. A31 MECHANISMS IN CYSTIC FIBROSIS AND OTHER BRONCHIECTATIC DISEASES: A Protein Complex Of Phe508del-Cftr, Nherf2, And Lpa2 Regulates Il-8 Secretion From Airway Epithelial Cells
El Taweel et al. Dectin-1 Is a Marker of Alternatively Activated Macrophages and a Therapeutic Target in Interstitial Fibrotic Lung Diseases
Coeman et al. Neomacrolides In The Treatment Of Patients With Severe Asthma And/or Bronchiectasis: A Promising Add-on Therapy
Gemicioglu et al. Asthma Control Test™(ACT) Scores and FeNO Correlation.
Jurja et al. Correlation between antioxidant activity of vegetal supplement and age related maculopathy
Zhang et al. A protein complex of Phe508del-CFTR, NHERF2, and LPA2 regulates IL-8 secretion from airway epithelial cells
Hozumi et al. Ykl-40 Is A Useful Biomarker For Evaluating Disease Activity And Predicting Prognosis In Patients With Polymyositis/dermatomyositis-Associated Interstitial Lung Disease
Herminawati et al. Dynamics of human mesenchymal stem cells, M1 microglia/macrophage, and fractalkine in ischemic stroke patients
Higano et al. MRI-based scoring of bronchopulmonary dysplasia (BPD) correlates with disease severity and short-term outcomes
Plante et al. D33 AIRWAY EPITHELIA ACTIVATION AND RESPONSES TO TREATMENT: Effect Of Mometasone And Formoterol On Proliferation Of Primary Airway Epithelial Cells Obtained From Mild Asthmatic Subjects
Sanda et al. ANTI-AGING EFFECT ON OCULAR TISSUES OF ANTIOXIDANT VEGETAL SUPPLEMENTS FROM ROMANIAN MARKET

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16762026

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017547484

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15556953

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2016762026

Country of ref document: EP